These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12666494)

  • 1. [Telithromycin, first ketolide].
    Van Laethem Y; Sternon J
    Rev Med Brux; 2003 Feb; 24(1):42-6. PubMed ID: 12666494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
    Reinert RR
    J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telithromycin. Aventis Pharma.
    Johnson AP
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1691-701. PubMed ID: 11892930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin.
    Zuckerman JM
    Infect Dis Clin North Am; 2004 Sep; 18(3):621-49, xi-. PubMed ID: 15308279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Macrolides and ketolides].
    Cobos-Trigueros N; Ateka O; Pitart C; Vila J
    Enferm Infecc Microbiol Clin; 2009; 27(7):412-8. PubMed ID: 19625112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Telithromycin].
    Benes J
    Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics.
    Fernandes P; Pereira D; Watkins PB; Bertrand D
    J Med Chem; 2020 Jun; 63(12):6462-6473. PubMed ID: 31644280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis.
    Buchanan PP; Stephens TA; Leroy B
    Am J Rhinol; 2003; 17(6):369-77. PubMed ID: 14750614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of new antibacterial therapies in at-risk populations.
    Lorenz J
    J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Macrolides, ketolides and streptogramins].
    Mensa J; García-Vázquez E; Vila J
    Enferm Infecc Microbiol Clin; 2003 Apr; 21(4):200-7; quiz 208, 219. PubMed ID: 12681133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002.
    Buxbaum A; Forsthuber S; Sauermann R; Gattringer R; Graninger W; Georgopoulos A;
    Int J Antimicrob Agents; 2004 Oct; 24(4):397-400. PubMed ID: 15380268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
    Norrby SR; Quinn J; Rangaraju M; Leroy B
    Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin: the first ketolide antimicrobial.
    Nguyen M; Chung EP
    Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telithromycin.
    Raja A; Lebbos J; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Sep; 3(9):733-4. PubMed ID: 15368658
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S; Hoban D;
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.